9.04
-0.26 (-2.80%)
| Previous Close | 9.30 |
| Open | 9.32 |
| Volume | 3,026,435 |
| Avg. Volume (3M) | 2,320,008 |
| Market Cap | 777,868,480 |
| Price / Sales | 18.83 |
| Price / Book | 9.32 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -416.67% |
| Diluted EPS (TTM) | -3.85 |
| Total Debt/Equity (MRQ) | 160.71% |
| Current Ratio (MRQ) | 5.80 |
| Operating Cash Flow (TTM) | -286.52 M |
| Levered Free Cash Flow (TTM) | -169.65 M |
| Return on Assets (TTM) | -36.29% |
| Return on Equity (TTM) | -93.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Syndax Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 120.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (BTIG, 519.47%) | Buy |
| Median | 35.00 (287.17%) | |
| Low | 24.00 (Goldman Sachs, 165.49%) | Buy |
| Average | 40.00 (342.48%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 13.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 05 Sep 2025 | 24.00 (165.49%) | Buy | 17.04 |
| 10 Jul 2025 | 18.00 (99.12%) | Buy | 9.82 | |
| Guggenheim | 04 Sep 2025 | 34.00 (276.11%) | Buy | 16.19 |
| BTIG | 05 Aug 2025 | 56.00 (519.47%) | Buy | 12.57 |
| Citigroup | 05 Aug 2025 | 51.00 (464.16%) | Buy | 12.57 |
| UBS | 15 Jul 2025 | 35.00 (287.17%) | Buy | 9.21 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Aug 2025 | Announcement | Syndax Announces Participation in September Investor Conferences |
| 04 Aug 2025 | Announcement | Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 28 Jul 2025 | Announcement | Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 |
| 24 Jun 2025 | Announcement | Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia |
| 12 Jun 2025 | Announcement | Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 |
| 12 Jun 2025 | Announcement | Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |